ProCE Banner Activity

ASPEN: Phase III Trial of Zanubrutinib vs Ibrutinib in Waldenström Macroglobulinemia

Slideset Download
Conference Coverage
Zanubrutinib demonstrated a nonsignificant improvement in response rate and lower rates of several adverse events vs ibrutinib in patients with Waldenström macroglobulinemia.

Released: June 09, 2020

Expiration: June 08, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono